Fr. 159.00

Signaling Pathways in Cancer Pathogenesis and Therapy

English · Paperback / Softback

Shipping usually within 6 to 7 weeks

Description

Read more

In recent years, increasing evidence has suggested that abnormal activation of signaling pathways is a critical event in cancer pathogenesis. In particular, activation of these pathways can lead to inappropriate cellular survival, proliferation, pluripotency, invasion, metastasis, and angiogenesis. Thus, understanding the mechanisms by which signaling pathways become subverted in a cancer cell can provide insight into critical events in cancer pathogenesis. Furthermore, as our ability to target specific molecular interactions advances, we now have the ability to design small molecules, protein therapeutics, and other forms of targeted therapies. By focusing on the specific molecular abnormalities in a cancer cell, these agents hold the potential to be much more effective and much less toxic than current cytotoxic therapies.

List of contents

Signaling Pathways in Cancer: 21st Century Approaches to Cancer Therapy.- Current And Next Generation Antimitotic Therapies In Cancer.- DNA Damage Checkpoint Signaling Pathways in Human Cancer.- Non-Receptor Tyrosine Kinases and their Roles in Cancer.- The Hedgehog Signaling Pathway in Cancer Pathogenesis and Therapy.- Wnt Signaling in Cancer Pathogenesis and Therapeutics.- STAT Signaling in the Pathogenesis and Treatment of Cancer.- Protein Therapeutics in Oncology.- Index

Summary

In recent years, increasing evidence has suggested that abnormal activation of signaling pathways is a critical event in cancer pathogenesis. In particular, activation of these pathways can lead to inappropriate cellular survival, proliferation, pluripotency, invasion, metastasis, and angiogenesis. Thus, understanding the mechanisms by which signaling pathways become subverted in a cancer cell can provide insight into critical events in cancer pathogenesis. Furthermore, as our ability to target specific molecular interactions advances, we now have the ability to design small molecules, protein therapeutics, and other forms of targeted therapies. By focusing on the specific molecular abnormalities in a cancer cell, these agents hold the potential to be much more effective and much less toxic than current cytotoxic therapies.

Product details

Assisted by Davi A Frank (Editor), David A Frank (Editor), David A. Frank (Editor)
Publisher Springer, Berlin
 
Languages English
Product format Paperback / Softback
Released 09.12.2013
 
EAN 9781489992222
ISBN 978-1-4899-9222-2
No. of pages 148
Dimensions 156 mm x 237 mm x 6 mm
Weight 268 g
Illustrations VIII, 148 p.
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

B, Pharmacology, Biomedical and Life Sciences, Cancer Research, Biomedical Research, Pharmacology/Toxicology

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.